Le Lézard
Classified in: Health
Subjects: ACC, SHM

Photocure ASA - Notice of the Annual General Meeting 3 May 2023


OSLO, Norway, April 12, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 3 May 2023 at 17:00 hours (CEST), virtual through the general meeting portal administered by Euronext Securities Oslo (the "Euronext Securities Portal").

The general meeting will be webcasted live and a link will be available on the company's website in due time in advance of the general meeting. It will not be possible to attend in person. Shareholders may also vote in advance or submit a proxy with voting instructions.

The notice convening the general meeting, including the agenda and the board's proposals to the matters to be dealt with, is enclosed with this notification and will be sent to all shareholders with known addresses.

Relevant documents referred to in the notice are made available on www.photocure.com.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: [email protected]

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

The following files are available for download:

https://mb.cision.com/Main/17498/3749685/1979962.pdf

Release

https://mb.cision.com/Public/17498/3749685/ab4c38b67c2b1f70.pdf

Notice of ordinary general meeting 2023 (English)

https://mb.cision.com/Public/17498/3749685/929534392275e8ae.pdf

Notice of ordinary general meeting 2023 (Norwegian)

 

SOURCE Photocure


These press releases may also interest you

at 02:05
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the appointments of Ashley Nagle as Chief Business Officer (CBO) and Peter Finan, currently a Non-Executive Director, as Non-Executive...

at 02:00
With Denmark as the centre of gravity, the ambition is to invest in, support and advance some of the world's most promising quantum technology companies with applications in the life sciences. The quantum industry, which develops novel technologies...

at 01:40
In a significant move to meet the growing demand for health management solutions, the 135th China Import and Export Fair ("Canton Fair" or "the Fair") has brought together top-tier companies from the Medicines, Health Products and Medical Devices...

at 00:05
As May marks Preeclampsia Awareness Month, leading maternal health experts, preeclampsia survivors and industry leaders have come together on a new campaign, "Preeclampsia Prevention is Possible." The campaign elevates awareness of a major paradigm...

30 avr 2024
The report titled "Clinical Trial Analytics Services Market by Services (Clinical Data Analytics, Clinical Trial Data Management, Clinical Trial Planning & Monitoring), Component (Data Management & Integrity Services, Data Visualization &...

30 avr 2024
Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi, chief physician of...



News published on and distributed by: